Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
NCT05502237 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1021
Last updated 2026-01-30
Summary
The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative to pembrolizumab (PEMBRO) in combination with chemotherapy on overall survival (OS) in patients with untreated metastatic non-small cell lung cancer with no actionable genomic alteration.
Conditions
Interventions
- DRUG
-
Zimberelimab
Administered intravenously
- DRUG
-
Domvanalimab
Administered intravenously
- DRUG
-
Administered intravenously
- DRUG
-
Administered intravenously
- DRUG
-
Administered intravenously
- DRUG
-
Administered intravenously
- DRUG
-
Administered intravenously
- DRUG
-
Pemetrexed
Administered intravenously
Sponsors & Collaborators
-
Arcus Biosciences, Inc.
collaborator INDUSTRY - lead INDUSTRY
Principal Investigators
-
Gilead Study Director · Gilead Sciences
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-10-12
- Primary Completion
- 2028-06-30
- Completion
- 2029-01-31
- FDA Drug
- Yes
Countries
- United States
- Argentina
- Austria
- Belgium
- Brazil
- Canada
- Chile
- China
- France
- Germany
- Hong Kong
- Israel
- Italy
- Japan
- Mexico
- Netherlands
- Portugal
- Singapore
- South Korea
- Spain
- Taiwan
- Turkey (Türkiye)
- United Kingdom
Study Locations
More Related Trials
-
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
NCT05676931 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)
NCT05599789 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
NCT06161441 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer
NCT02733250 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
NCT06312137 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT04619797 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
NCT03976323 ·Status: COMPLETED ·Phase: PHASE3
-
Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC
NCT04153734 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)
NCT00527735 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)
NCT03302234 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT01160744 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
NCT00870870 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer
NCT02581943 ·Status: COMPLETED ·Phase: PHASE2
-
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05211895 ·Status: RECRUITING ·Phase: PHASE3
-
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)
NCT06788912 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer
NCT05005273 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer
NCT02259582 ·Status: COMPLETED ·Phase: PHASE2
-
Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer
NCT05882513 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Switch Maintenance Pembrolizumab in Patients With NSCLC After First Line Platinum Doublet Chemotherapy
NCT02705820 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin
NCT02279732 ·Status: COMPLETED ·Phase: PHASE3
-
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738 ·Status: RECRUITING ·Phase: PHASE3
-
Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
NCT05226598 ·Status: COMPLETED ·Phase: PHASE3
-
Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
NCT00052338 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer
NCT05775289 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
NCT06731907 ·Status: RECRUITING ·Phase: PHASE2